Cambrex Corporation (CBM) VP Samantha Hanley Sells 14,000 Shares
Cambrex Corporation (NYSE:CBM) VP Samantha Hanley sold 14,000 shares of Cambrex Corporation stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $57.56, for a total transaction of $805,840.00. Following the sale, the vice president now owns 1,500 shares of the company’s stock, valued at approximately $86,340. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Cambrex Corporation (NYSE:CBM) traded up 0.26% on Monday, reaching $57.95. 282,935 shares of the company traded hands. The firm has a 50 day moving average of $54.99 and a 200-day moving average of $53.85. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The stock has a market capitalization of $1.89 billion, a PE ratio of 22.06 and a beta of 2.42.
Cambrex Corporation (NYSE:CBM) last released its earnings results on Thursday, May 4th. The biotechnology company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.17. The business had revenue of $105.01 million during the quarter, compared to the consensus estimate of $99.05 million. Cambrex Corporation had a net margin of 17.36% and a return on equity of 24.92%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.50 EPS. On average, analysts anticipate that Cambrex Corporation will post $3.02 EPS for the current year.
CBM has been the topic of several recent analyst reports. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Cambrex Corporation from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Investment Research raised shares of Cambrex Corporation from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Cambrex Corporation presently has a consensus rating of “Buy” and a consensus target price of $64.00.
A number of hedge funds have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC increased its stake in Cambrex Corporation by 3.8% in the first quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after buying an additional 68 shares in the last quarter. YorkBridge Wealth Partners LLC increased its stake in Cambrex Corporation by 20.2% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,874 shares of the biotechnology company’s stock worth $106,000 after buying an additional 315 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Cambrex Corporation during the first quarter worth $109,000. Dubuque Bank & Trust Co. purchased a new stake in Cambrex Corporation during the first quarter worth $144,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in Cambrex Corporation during the first quarter worth $151,000. 98.28% of the stock is owned by institutional investors and hedge funds.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.